Despite the availability of the drug treatment for tuberculosis (TB) more than 75 years, mortality and drug resistance are increasing. Therefore, little data is available in Guinea. We aimed to develop and validate a prognosis nomogram of MDR-TB treatment outcomes. A retrospective cohort study was conducted among men and women, aged 18 years or older, with MDR-TB, from three major drug-resistance TB centres in Guinea. We used the logistic regression to analyse treatment outcomes. Prognostic factors with a p value less than 0.05 from a multivariate model were used to build nomogram and assessed their performance based on discriminative c-index, and calibration using the Hosmer-Lemeshow (H-L) test. To derive the optimal cut-off point score, the Youden’s index method was used. Among 232 patients with MDR-TB enrolled and followed between June 07, 2016 and June 22, 2018, 218 were analyzed. All patients were resistant to rifampicin, which diagnosed by the Xpert MTB/RIF. The overall rate of success was 73%. Factors associated with successful treatment in drug-resistant TB patients were higher BMI more than 18.5 kg/m2 (p = 0.0253; aOR = 2.94), good adherence to treatment (p = < 0.0001; aOR = 33.92), normal platelets count (p = 0.0053; OR = 1.004), and the absence of clinical symptoms such as chest pain (p = 0.0083; aOR = 3.19) and depression (p = 0.0308; aOR = 8.62). The discrimination (c-index = 0.848 [95% bootstrap CI, 0.780 – 0.916] in the derivation sample and 0.803 after correction for optimism) and calibration (H-LX2 = 2.91 [p = 0.94]) were good. The optimal absolute risk threshold was 20%, corresponding to a sensibility of 95% and specificity of 58%. Treatment success outcomes was lower than those recommended by the World Health Organization (75%). We recommend to improve the MDR-TB patient monitoring during treatment, nutritional status, and considering the psychological state. Our prognosis nomogram needs to be validated in an external population before it can be used in clinical practice.
| Published in | Central African Journal of Public Health (Volume 6, Issue 1) |
| DOI | 10.11648/j.cajph.20200601.16 |
| Page(s) | 33-41 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Nomogram, Multidrug-resistant, Tuberculosis, Guinea
| [1] | Caminero JA. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2010; 14 (4): 382–90. |
| [2] | World Health Organization: Global tuberculosis report 2017. Geneva, Swizerland: WHO press, 2017. |
| [3] | National Tuberculosis Control Program Guinea: Annual report of TB control activity, 2018. |
| [4] | Bastos ML, Cosme LB, Fregona G, do Prado TN, Bertolde AI, Zandonade E, et al. Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis. BMC Infect Dis. 2017; 17 (1). |
| [5] | El Hamdouni M, Bourkadi JE, Benamor J, Hassar M, Cherrah Y, Ahid S. Treatment outcomes of drug resistant tuberculosis patients in Morocco: multi-centric prospective study. BMC Infect Dis. 2019; 19 (1): 316. |
| [6] | Leveri TH, Lekule I, Mollel E, Lyamuya F, Kilonzo K. Predictors of Treatment Outcomes among Multidrug Resistant Tuberculosis Patients in Tanzania. Tuberc Res Treat.; 2019: 1–10. |
| [7] | Jaber AAS, Ibrahim B. Evaluation of risk factors associated with drug-resistant tuberculosis in Yemen: data from centres with high drug resistance. BMC Infect Dis. 2019; 19 (1): 464. |
| [8] | Khan I, Ahmad N, Khan S, Muhammad S, Ahmad Khan S, Ahmad I, et al. Evaluation of treatment outcomes and factors associated with unsuccessful outcomes in multidrug resistant tuberculosis patients in Baluchistan province of Pakistan. J Infect Public Health. 2019; |
| [9] | Lin C-B, Sun H-C, Chiang C-Y, Wu C-W, Chou H-W, Tang T-Q, et al. Treatment outcomes for multidrug-resistant tuberculosis in Eastern Taiwan. Tzu Chi Med J. 2019; 31 (1): 35. |
| [10] | Muvunyi CM, Ngabonziza JCS, Uwimana I, Harelimana JDD, Mucyo Y, Sebatunzi OR, et al. Highly successful treatment outcome of multidrug-resistant and genetic diversity of multidrug-resistant Mycobacterium tuberculosis strains in Rwanda. Trop Med Int Health. 2019; 24 (7): 879-887. |
| [11] | Yunusbaeva M, Borodina L, Alekseev P, Davydov R, Yunusbaev U, Sharipov R, et al. Treatment efficacy of drug-resistant tuberculosis in Bashkortostan, Russia: A retrospective cohort study. Int J Infect Dis. 2019; 81: 203–9. |
| [12] | Samuels JP, Sood A, Campbell JR, Ahmad Khan F, Johnston JC. Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis. Sci Rep. 2018; 8 (1). |
| [13] | Falzon D, Schünemann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017; 49 (3): 1602308. |
| [14] | Hansen RA, Kim MM, Song L, Tu W, Wu J, Murray MD. Adherence: Comparison of Methods to Assess Medication Adherence and Classify Nonadherence. Ann Pharmacother. 2009; 43 (3): 413–22. |
| [15] | WHO: Definitions and reporting framework for tuberculosis – 2013 revision (updated 2014). Geneva: Switzerland World Health Organization; 2013. |
| [16] | Hosmer DW, Lemeshow S. Applied logistic regression [Internet]. New York; Toronto: John Wiley & Sons; 2005. |
| [17] | Youden WJ. Index for rating diagnostic tests. Cancer. 1950; 3 (1): 32–5. |
| [18] | Kliiman K, Altraja A. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J. 2009; 33 (5): 1085–94. |
| [19] | Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, et al. Outcomes of Patients With Multidrug-Resistant Pulmonary Tuberculosis Treated With Ofloxacin/Levofloxacin-Containing Regimens. Chest. 2000; 117 (3): 744–51. |
| [20] | Byrd, Jr. RP, Mehta JB, Roy TM. Malnutrition and Pulmonary Tuberculosis. Clin Infect Dis. 2002; 35 (5): 634–5. |
| [21] | Nellums LB, Rustage K, Hargreaves S, Friedland JS. Multidrug-resistant tuberculosis treatment adherence in migrants: a systematic review and meta-analysis. BMC Med. 2018; 16 (1). |
| [22] | Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999; 282 (18): 1737–44. |
APA Style
Boubacar Djelo Diallo, Alhassane Diallo, Lansana Mady Camara, Mafouné Diallo, Souleymane Camara, et al. (2020). Development of a Prognosis Nomogram of Treatment Outcomes for MDR-tuberculosis in Guinea (Conakry): A Retrospective Cohort Analysis. Central African Journal of Public Health, 6(1), 33-41. https://doi.org/10.11648/j.cajph.20200601.16
ACS Style
Boubacar Djelo Diallo; Alhassane Diallo; Lansana Mady Camara; Mafouné Diallo; Souleymane Camara, et al. Development of a Prognosis Nomogram of Treatment Outcomes for MDR-tuberculosis in Guinea (Conakry): A Retrospective Cohort Analysis. Cent. Afr. J. Public Health 2020, 6(1), 33-41. doi: 10.11648/j.cajph.20200601.16
AMA Style
Boubacar Djelo Diallo, Alhassane Diallo, Lansana Mady Camara, Mafouné Diallo, Souleymane Camara, et al. Development of a Prognosis Nomogram of Treatment Outcomes for MDR-tuberculosis in Guinea (Conakry): A Retrospective Cohort Analysis. Cent Afr J Public Health. 2020;6(1):33-41. doi: 10.11648/j.cajph.20200601.16
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.cajph.20200601.16,
author = {Boubacar Djelo Diallo and Alhassane Diallo and Lansana Mady Camara and Mafouné Diallo and Souleymane Camara and Boubacar Bah and Magassouba Aboubacar Sidiki and Alpha Oumar Barry and Thierno Hassane Diallo and Oumou Younoussa Sow},
title = {Development of a Prognosis Nomogram of Treatment Outcomes for MDR-tuberculosis in Guinea (Conakry): A Retrospective Cohort Analysis},
journal = {Central African Journal of Public Health},
volume = {6},
number = {1},
pages = {33-41},
doi = {10.11648/j.cajph.20200601.16},
url = {https://doi.org/10.11648/j.cajph.20200601.16},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cajph.20200601.16},
abstract = {Despite the availability of the drug treatment for tuberculosis (TB) more than 75 years, mortality and drug resistance are increasing. Therefore, little data is available in Guinea. We aimed to develop and validate a prognosis nomogram of MDR-TB treatment outcomes. A retrospective cohort study was conducted among men and women, aged 18 years or older, with MDR-TB, from three major drug-resistance TB centres in Guinea. We used the logistic regression to analyse treatment outcomes. Prognostic factors with a p value less than 0.05 from a multivariate model were used to build nomogram and assessed their performance based on discriminative c-index, and calibration using the Hosmer-Lemeshow (H-L) test. To derive the optimal cut-off point score, the Youden’s index method was used. Among 232 patients with MDR-TB enrolled and followed between June 07, 2016 and June 22, 2018, 218 were analyzed. All patients were resistant to rifampicin, which diagnosed by the Xpert MTB/RIF. The overall rate of success was 73%. Factors associated with successful treatment in drug-resistant TB patients were higher BMI more than 18.5 kg/m2 (p = 0.0253; aOR = 2.94), good adherence to treatment (p = c-index = 0.848 [95% bootstrap CI, 0.780 – 0.916] in the derivation sample and 0.803 after correction for optimism) and calibration (H-LX2 = 2.91 [p = 0.94]) were good. The optimal absolute risk threshold was 20%, corresponding to a sensibility of 95% and specificity of 58%. Treatment success outcomes was lower than those recommended by the World Health Organization (75%). We recommend to improve the MDR-TB patient monitoring during treatment, nutritional status, and considering the psychological state. Our prognosis nomogram needs to be validated in an external population before it can be used in clinical practice.},
year = {2020}
}
TY - JOUR T1 - Development of a Prognosis Nomogram of Treatment Outcomes for MDR-tuberculosis in Guinea (Conakry): A Retrospective Cohort Analysis AU - Boubacar Djelo Diallo AU - Alhassane Diallo AU - Lansana Mady Camara AU - Mafouné Diallo AU - Souleymane Camara AU - Boubacar Bah AU - Magassouba Aboubacar Sidiki AU - Alpha Oumar Barry AU - Thierno Hassane Diallo AU - Oumou Younoussa Sow Y1 - 2020/01/16 PY - 2020 N1 - https://doi.org/10.11648/j.cajph.20200601.16 DO - 10.11648/j.cajph.20200601.16 T2 - Central African Journal of Public Health JF - Central African Journal of Public Health JO - Central African Journal of Public Health SP - 33 EP - 41 PB - Science Publishing Group SN - 2575-5781 UR - https://doi.org/10.11648/j.cajph.20200601.16 AB - Despite the availability of the drug treatment for tuberculosis (TB) more than 75 years, mortality and drug resistance are increasing. Therefore, little data is available in Guinea. We aimed to develop and validate a prognosis nomogram of MDR-TB treatment outcomes. A retrospective cohort study was conducted among men and women, aged 18 years or older, with MDR-TB, from three major drug-resistance TB centres in Guinea. We used the logistic regression to analyse treatment outcomes. Prognostic factors with a p value less than 0.05 from a multivariate model were used to build nomogram and assessed their performance based on discriminative c-index, and calibration using the Hosmer-Lemeshow (H-L) test. To derive the optimal cut-off point score, the Youden’s index method was used. Among 232 patients with MDR-TB enrolled and followed between June 07, 2016 and June 22, 2018, 218 were analyzed. All patients were resistant to rifampicin, which diagnosed by the Xpert MTB/RIF. The overall rate of success was 73%. Factors associated with successful treatment in drug-resistant TB patients were higher BMI more than 18.5 kg/m2 (p = 0.0253; aOR = 2.94), good adherence to treatment (p = c-index = 0.848 [95% bootstrap CI, 0.780 – 0.916] in the derivation sample and 0.803 after correction for optimism) and calibration (H-LX2 = 2.91 [p = 0.94]) were good. The optimal absolute risk threshold was 20%, corresponding to a sensibility of 95% and specificity of 58%. Treatment success outcomes was lower than those recommended by the World Health Organization (75%). We recommend to improve the MDR-TB patient monitoring during treatment, nutritional status, and considering the psychological state. Our prognosis nomogram needs to be validated in an external population before it can be used in clinical practice. VL - 6 IS - 1 ER -
Information
Email: